Literature DB >> 8732680

Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.

J S Foster1, J Wimalasena.   

Abstract

Cyclin-dependent kinases (Cdk) act to regulate G1- to S-phase transition in mammalian cells. We have studied the effects of estradiol and the steroidal antiestrogen ICI 182, 780 on induction of Cdk activity and the consequent phosphorylation of retinoblastoma protein (Rb) in estrogen-responsive MCF-7 breast cancer cells. Treatment of growth-arrested MCF-7 cells with physiological concentrations of estradiol led to a time-dependent increase in Cdk2-associated and cyclin E-dependent kinase activity, which was accompanied by hyperphosphorylation of Rb and S-phase entry. Induction of both Cdk2 activity and DNA synthesis by estradiol was dose dependent and was inhibited by coadministration of ICI 182,780. Elicitation of Cdk2 activity was found to require prolonged (> 8h) estradiol exposure. Levels of cyclins E and A were unchanged in MCF-7 cells undergoing G1- to S-transit; however, synthesis and steady state levels of cyclin D1 protein were increased by estradiol. Cdk4-associated Rb kinase activity was evident in MCF-7 cells by 6 h after estradiol exposure and was inhibited by antiestrogen. Cdk2 and Cdk4 protein levels were not altered by estrogen treatment; however, faster migrating, phosphorylated Cdk2 forms increased in estradiol-treated MCF-7 cells by 12 after release from growth arrest. Cdtk-inhibitory activities, associated with p27kip-1, were eliminated from growth-arrested MCF-7 cells after treatment with estradiol but were not eliminated from cells cotreated with estradiol and ICI 182,780. These findings suggest that estradiol regulates G1 progression in MCF-7 cells through direct effects upon Cdk activation, Rb phosphorylation, and by inducing elimination of Cdk inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732680     DOI: 10.1210/mend.10.5.8732680

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  48 in total

1.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

2.  The nuclear orphan receptors COUP-TF and ARP-1 positively regulate the trout estrogen receptor gene through enhancing autoregulation.

Authors:  G Lazennec; L Kern; Y Valotaire; G Salbert
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  Prediction of functional phosphorylation sites by incorporating evolutionary information.

Authors:  Shen Niu; Zhen Wang; Dongya Ge; Guoqing Zhang; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

5.  Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice.

Authors:  Mengyuan Du; Xujuan Yang; James A Hartman; Paul S Cooke; Daniel R Doerge; Young H Ju; William G Helferich
Journal:  Carcinogenesis       Date:  2012-01-20       Impact factor: 4.944

6.  Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.

Authors:  H Ikeda; T Yoshimoto; N Shida; I Miyoshi; K Nakayama; K Nakayama; M Oshima; M M Taketo
Journal:  Endocrine       Date:  2001-10       Impact factor: 3.633

7.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

Review 8.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

9.  Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.

Authors:  William R Miller; Alexey Larionov
Journal:  Breast Cancer Res       Date:  2010-07-20       Impact factor: 6.466

Review 10.  Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Authors:  Joan S Lewis-Wambi; V Craig Jordan
Journal:  Breast Cancer Res       Date:  2009-05-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.